To the full analysis
Halozyme Therapeutics stock: growth
HALOHalozyme Therapeutics reported $1.4B in revenue for fiscal 2025, up 37.6% on the prior year, up 39.2% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
46.5%
per year from 2006 to 2025, per share 41.6%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
27.2%
per year from 2006 to 2025, per share 22.9%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 39.2% | 26.3% | 46.5% |
| Revenue per share | 42.8% | 27.0% | 41.6% |
| Earnings | 19.7% | no data | no data |
| Earnings per share | 22.7% | no data | no data |
| Free cash flow | 64.8% | no data | 27.2% |
| Free cash flow per share | 69.1% | no data | 22.9% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $981.75K | −$14.75M | $6.71M |
| 2007 | $3.8M | −$23.9M | −$2.51M |
| 2008 | $8.76M | −$48.65M | −$36.53M |
| 2009 | $13.67M | −$58.36M | −$41.61M |
| 2010 | $13.62M | −$53.24M | −$46.03M |
| 2011 | $56.09M | −$19.77M | −$35.18M |
| 2012 | $42.33M | −$53.55M | −$65.74M |
| 2013 | $54.8M | −$83.48M | −$51.64M |
| 2014 | $75.33M | −$68.38M | −$48.89M |
| 2015 | $135.06M | −$32.23M | −$39.44M |
| 2016 | $146.69M | −$103.02M | −$53.52M |
| 2017 | $316.61M | $62.97M | $132.7M |
| 2018 | $151.86M | −$80.33M | −$54.16M |
| 2019 | $195.99M | −$72.24M | −$89.46M |
| 2020 | $267.59M | $129.09M | $52.95M |
| 2021 | $443.31M | $402.71M | $297.98M |
| 2022 | $660.12M | $202.13M | $235.3M |
| 2023 | $829.25M | $281.59M | $373.28M |
| 2024 | $1.02B | $444.09M | $468.37M |
| 2025 | $1.4B | $316.89M | $644.59M |
Revenue by region
Where Halozyme Therapeutics, Inc. generates its revenue.
- Switzerland72%
- United States27%
Figures as a table
| 2016 | 2017 | 2018 | Share 2018 | |
|---|---|---|---|---|
| Switzerland | $93.07M | $119.14M | $109.89M | 72.4% |
| United States | $52.29M | $196.27M | $40.48M | 26.7% |
| Total revenue | $146.69M | $316.61M | $151.86M | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 22 Nov 2024)
- Valuation signal Undervalued since 7 Nov 2026, previously Fairly valued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.